Detail
| LncRNA Name | CCAT2 |
| Synonyms | CCAT2, LINC00873, NCCP1 |
| Region | GRCh38_8:127400399-127402150 Sequence |
| Ensembl | ENSG00000280997 |
| RefSeq | NR_109834 |
| Circulating | ✘ |
| Drug-resisitant | ✘ |
| Prognostic | ✔ |
| MiRNA | ✘ |
| Variant | ✘ |
| TF | ✘ |
| Methylation | ✘ |
| Cancer Name | prostate cancer |
| ICD-0-3 | C61.9 |
| Methods | qPCR, RNAi, Western blot, Cell proliferation assay etc. |
| Sample | prostate cancer tissues, cell lines (DU-145, 22RV1, WPMY-1) |
| Expression Pattern | up-regulated |
| Function Description | We found that the expression level of CCAT2 was higher in PCa tissues and cells compared to adjacent non-tumor tissues and normal prostate stromal immortalized cells WPMY-1. We also found that knockdown of CCAT2 could inhibit cell growth, migration, and invasion in vitro. In addition, knockdown of CCAT2 stimulated epithelial-mesenchymal transition (EMT) through abrogating N-cadherin, vimentin expression and intensifing the expression levels of E-cadherin. |
| Pubmed ID | 27558961 |
| Year | 2016 |
| Title | The up-regulation of long non-coding RNA CCAT2 indicates a poor prognosis for prostate cancer and promotes metastasis by affecting epithelial-mesenchymal transition. |
| External Links |
| Links for CCAT2 | GenBank HGNC lncrnadb Noncode |
| Links for prostate cancer | Omim Cosmic |
CopyRight © College of Bioinformatics Science and Technology, Harbin Medical University, China.